Tags

Type your tag names separated by a space and hit enter

COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 03 28; 395(10229):1033-1034.Lct

Links

Publisher Full Text
ncbi.nlm.nih.gov
linkinghub.elsevier.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Mehta P
Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.
McAuley DF
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.
Brown M
Hospital for Tropical Diseases, University College London Hospital, London NW1 2PG, UK.
Sanchez E
Department of Clinical Virology, University College London Hospital, London NW1 2PG, UK.
Tattersall RS
Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.
Manson JJ
Department of Rheumatology, University College London Hospital, London NW1 2PG, UK. Electronic address: jessica.manson@nhs.net.
HLH Across Speciality Collaboration, UK
No affiliation info available

MeSH

Antirheumatic AgentsBetacoronavirusCOVID-19Coronavirus InfectionsCytokinesHumansImmunization, PassiveImmunoglobulins, IntravenousImmunosuppressionImmunosuppressive AgentsInflammationPandemicsPneumonia, ViralSARS-CoV-2Steroids

Pub Type(s)

Letter

Language

eng

PubMed ID

32192578

Clinical Trial Links

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
Anti COVID-19 Convalescent Plasma Therapy
Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease
Modulation of Hyperinflammation in COVID-19
Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)
Pilot Study on Cytokine Filtration in COVID-19 ARDS
Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
Using GM-CSF as a Host Directed Therapeutic Against COVID-19
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients
Primary Prevention of Infection by COVID-19 in Health Providers
Evaluation of Immune Response in COVID-19 Patients
Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection
Hemostasis in COVID-19: an Adaptive Clinical Trial
COVID-19 - Cytokine Storm
Extracorporeal Blood Purification as a Treatment Modality for COVID-19
Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
Clazakizumab vs. Placebo - COVID-19 Infection
Allocetra-OTS in COVID-19
Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia
Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist
Cytokine Storm Among Bangladeshi Patients With COVID-19
Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine
Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care

Citation

Mehta, Puja, et al. "COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression." Lancet (London, England), vol. 395, no. 10229, 2020, pp. 1033-1034.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Mehta P, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet. 2020 03 28;395(10229):1033-1034. PubMed PMID: 32192578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19: consider cytokine storm syndromes and immunosuppression. AU - Mehta,Puja, AU - McAuley,Daniel F, AU - Brown,Michael, AU - Sanchez,Emilie, AU - Tattersall,Rachel S, AU - Manson,Jessica J, AU - ,, Y1 - 2020/03/16/ PY - 2020/03/08/received PY - 2020/03/11/accepted PY - 2020/3/21/pubmed PY - 2020/4/4/medline PY - 2020/3/21/entrez SP - 1033 EP - 1034 JF - Lancet (London, England) JO - Lancet VL - 395 IS - 10229 SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/32192578/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30628-0 DB - PRIME DP - Unbound Medicine ER -